{"prompt": "['in addition to condom use by her male partner(s) from the date of', 'screening until 30 days after the last dose of study drug', '8. All male study participants must agree to consistently and correctly use', 'condoms with their female partner(s) of childbearing potential and such', 'female partner(s) must agree to use an acceptable method of birth control', '(listed) from the date of screening until 90 days after the last dose of study', 'drug', '9. Male subjects must refrain from sperm donation from the date of screening', 'until 90 days after the last dose of study drug', '10. Subject must be in generally good health, with the exception of HCV, in the', 'opinion of the Sponsor-Investigator or Sub-Investigator(s)', '11. Subject must be able to comply with dosing instructions for study drug', 'administration and able to complete the study visits, including all required', 'post-treatment visits', 'Exclusion Criteria for clinical subjects:', 'Subjects who meet any of the following exclusion criteria are not to be enrolled in', 'this study:', '1. Presence of decompensated cirrhosis as defined by encephalopathy, ascites,', 'or a history of a variceal bleed', '2.', 'Prior treatment with direct acting antiviral hepatitis C medications', '3. Positive urine drug toxicity test at screening (except for cannabinoids and', 'prescribed medications)', '4.', 'Absence of buprenorphine in urine sample at screening', '5. Currently pregnant or breastfeeding female', '6.', 'Detectable HIV RNA > 50 copies/ml (co-infected subjects with suppressed', 'viral load ARE eligible for participation)', '7. Use of any prohibited concomitant medication within 28 days prior to day 1', '8.', 'Chronic use of systemically administered immunosuppressive agents', '9. Difficulty with blood collection or poor venous access', '10. History of solid organ transplantation', '11. Known significant allergy to sofosbuvir or velpatasvir', '12. Current chronic liver disease of a non-HCV etiology (including', \"hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency)\", '13. Active HBV infection defined as either a positive HBV surface antigen test or', 'a positive test for HBV DNA. (Subjects who are positive for HBV core', 'antibody but negative for Hepatitis B sAb, sAg, and DNA ARE eligible)', 'Eligibility Criteria for Provider Participants', 'All licensed buprenorphine/naloxone providers who are also licensed staff psychiatrists at the outpatient', 'addiction clinic at Cambridge Health Alliance are eligible to participate in the study. Participation will', 'require', '1. Attendance at the teaching session on the evaluation and management of', 'hepatitis C infection conducted by the Study Investigator, Dr. Amy Colson (see', 'Appendix 6 for teaching curriculum)', 'CRI 15-05 Protocol 13SEP2017', 'Page 7']['2. Agreement to have weekly mentorship by telephone with Dr. Colson.', '3. Provision of written informed consent addressing survey completion', 'Study Procedures', '/Frequency:', 'All study procedures will take place at the buprenorphine-naloxone clinic at OAS.', 'Subjects will be seen approximately biweekly, in conjunction with their visits to', 'the outpatient addiction clinic. Effectiveness of HCV treatment will be assessed', 'at week 4 on treatment and at 4 and 12 weeks following completion of', 'treatment by measuring HCV RNA using the Cobas AmpliPrep/Cobas TaqMan\u00ae', 'HCV Test V 2.0.', 'Liver fibrosis will be assessed by Hepatitis C Virus (HCV) FibroSure\u00ae test collected', 'at the screening visit as well as by FIB-4 index calculated from ALT, AST and', 'platelet count collected at the screening visit. To the extent that the two tests', 'differ, the higher fibrosis score will be used to guide therapy. Additional', 'screening labs will include: ALT, AST, HgbA1C, indirect bilirubin, direct bilirubin,', 'alkaline phosphatase, CBC with Platelet Count, basic metabolic panel with', 'calculated GFR, Hepatitis B surface antibody, Hepatitis B core antibody, Hepatitis', 'B surface antigen, Hepatitis B quantitative DNA, HCV genotype (if not', 'documented in the medical record), urine drug screen (for natural and synthetic', 'opioids, cocaine, benzodiazepines, cannabinoids, barbiturates, and', 'buprenorphine), and serum pregnancy test for women of childbearing', 'potential).', 'All women of childbearing potential will be screened for pregnancy throughout', 'study participation, and pregnancy prevention counseling will be offered to', 'women of childbearing potential and all male participants. Urine drug screening', 'will occur at every visit. Additional laboratory assessments may be conducted', 'per standard of care for monitoring of health or adverse events, throughout the', 'study. All laboratory assessments will be conducted as standard of care', 'assessments.', 'At the screening visit, study participants will complete questionnaires assessing', 'demographic characteristics. At baseline, week 4 on-treatment, end of', 'treatment (or early termination), and 12 weeks after treatment, participants will', 'complete quality of life questionnaires including the Functional Assessment of', 'Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS v1.0 Emotional Distress -', 'Depression Short Form 8a (PROMIS ED -Depression SF8a), and Short Form Health', 'Survey (SF36).', 'Adherence to Epclusa will be monitored at each study treatment visit through', 'pill counts and MEMSCap\u2122 Medication Event Monitoring System smart', 'packaging that records the date and time whenever the medication vial is', 'opened.', 'CRI 15-05 Protocol 13SEP2017', 'Page 8']\n\n###\n\n", "completion": "END"}